NCT00439621View on ClinicalTrials.gov

Safety Study of Anti-IgE Immunotherapy in Allergic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

August 31, 2008

Conditions
Allergy
Interventions
BIOLOGICAL

RP 01

Active immunotherapy

Trial Locations (2)

Unknown

P3 Research, Tauranga

P3 Research, Wellington

All Listed Sponsors
lead

Resistentia Pharmaceuticals AB

INDUSTRY

NCT00439621 - Safety Study of Anti-IgE Immunotherapy in Allergic Patients | Biotech Hunter | Biotech Hunter